Broad Spectrum Antimicrobials (BSA)

Joe Larsen, Ph.D.
Branch Chief

BARDA Industry Day
November 12, 2013
Antimicrobial Resistance Threat

- 2M infections per year caused by AMR pathogens
- 23,000 deaths annually in US
- Estimated economic burden of $20-35B annually
- Categories of AMR pathogens in terms of public health threat: Urgent, Serious, or Concerning
BSA Program Strategy

• **Revitalize** the antibacterial pipeline through the support of public private partnerships targeting novel unprecedented and preceded classes of antibiotics

• **Emphasize** programs that address the immediate public health threat of MDR strains of hospital and community acquired pathogens

• **Provide** a biodefense capability to bridge the response between the first clinical case of threat agent infection to when mass dispensing of MCMs is initiated

• **Enable** the evaluation of products for all biothreat pathogens via the development of animal models and tools to support regulatory approval
BSA Program

• Why invest in antimicrobials as a preparedness capability?
  — AMR will complicate the response to ANY public health emergency
  — Commercial indications are a prerequisite to label expansion for biodefense
  — Supplements the public health emergency response until mass points of dispensing are established
  — Commercial availability reduces life cycle management cost
BSA Priorities

Biothreat
- *B. pseudomallei*
- *B. mallei*
- *F. tularensis*
- *Y. pestis*
- *B. anthracis*

Antibiotic Resistance
- CRE
- Acinetobacter
- Pseudomonas
- MDR-GC
- ESBL
- MRSA
- VRE

Drug Class
- Unprecedented
  - Novel Target
  - Novel Chemistry
- Precedented
  - Reduced AR
  - Improved Safety
  - Improved Dosing
  - Special Populations
• Summary:

— The BSA program will continue to support the development of novel antimicrobials for the treatment and prevention of biological threat agent infection while concurrently addressing the growing public health threat of antimicrobial resistance

— Actively seek partnership opportunities with companies to bolster antimicrobial development and mitigate risk for biodefense drug development

— Additional contract awards projected in FY14
Interfacing with BARDA

- **www.phe.gov**
  - Program description, information, news, announcements

- **www.medicalcountermeasures.gov**
  - Portal to BARDA
  - Register, request a meeting
  - Tech Watch

- **www.fedbizopps.gov**
  - Official announcements and detailed information about all government contract solicitations

Technical POC for Research Area #3: Antimicrobial Drugs:
Joe Larsen, Ph.D. Chief BSA Program
joseph.larsen@hhs.gov   202-260-0050